News >

Targeted Agents and Immunotherapy Revamp Treatment in HCC, While Biomarkers Remain Elusive

Jessica Hergert
Published: Friday, Mar 13, 2020

Richard Finn, MD, assistant professor of Medicine at the Geffen School of Medicine at UCLA

Richard S. Finn, MD

A flood of targeted therapy and immunotherapy options to both the first- and second-line settings of hepatocellular carcinoma (HCC) has had significant implications on the treatment of patients in this space and will likely create challenges regarding sequencing, said Richard S. Finn, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication